



L Number	Hits	Search Text	DB	Time stamp
1	7926	((540/578) or (544/122) or (544/124) or (544/324) or (544/330) or (544/331) or (544/333) or (546/82) or (546/118) or (546/167) or (546/193) or (546/199) or (546/271.7) or (546/273.1) or (546/273.4) or (548/143) or (548/222) or (548/304.7) or (548/305.1) or (548/306.1) or (548/308.1)).CCLS.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/06 17:43
2	8021	((514/215) or (514/234.5) or (514/252.14) or (514/252.19) or (514/256) or (514/269) or (514/275) or (514/293) or (514/303) or (514/314) or (514/318) or (514/322) or (514/338) or (514/364) or (514/375) or (514/395)).CCLS.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/06 17:46
3	13274	((540/578) or (544/122) or (544/124) or (544/324) or (544/330) or (544/331) or (544/333) or (546/82) or (546/118) or (546/167) or (546/193) or (546/199) or (546/271.7) or (546/273.1) or (546/273.4) or (548/143) or (548/222) or (548/304.7) or (548/305.1) or (548/306.1) or (548/308.1)).CCLS.) or ((514/215) or (514/234.5) or (514/252.14) or (514/252.19) or (514/256) or (514/269) or (514/275) or (514/293) or (514/303) or (514/314) or (514/318) or (514/322) or (514/338) or (514/364) or (514/375) or (514/395)).CCLS.)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/06 17:46



chain nodes :

12 13 15 16

ring nodes :

1 2 3 4 5 6 7 8 9

ring/chain nodes :

14

chain bonds :

8-12 12-13 13-14 13-15

ring bonds :

1-2 1-6 1-9 2-3 3-4 4-5 5-6 6-7 7-8 8-9

exact/norm bonds :

1-2 1-6 1-9 2-3 3-4 4-5 5-6 6-7 7-8 8-9 8-12 12-13 13-14 13-15

G1:C,N

G2:O,N



Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 12:CLASS 13:CLASS  
14:CLASS 15:CLASS 16:Atom 17:CLASS

Generic attributes :

16:

Saturation : Unsaturated



chain nodes :

12 13 15

ring nodes :

1 2 3 4 5 6 7 8 9 16

ring/chain nodes :

14

chain bonds :

3-16 8-12 12-13 13-14 13-15

ring bonds :

1-2 1-6 1-9 2-3 3-4 4-5 5-6 6-7 7-8 8-9

exact/norm bonds :






1-2 1-6 1-9 2-3 3-4 3-16 4-5 5-6 6-7 7-8 8-9 8-12 12-13 13-14 13-15

G1:C,N

G2:O,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 12:CLASS 13:CLASS  
14:CLASS 15:CLASS 16:Atom



chain nodes :

12 13 15 34

ring nodes :

1 2 3 4 5 6 7 8 9 16 17 18 19 20 21 22 23 24 25 28

ring/chain nodes :

14

chain bonds :

12-13 12-34 13-14 13-15

ring bonds :

1-2 1-6 1-9 2-3 3-4 4-5 4-25 5-6 5-25 6-7 7-8 8-9 16-17 16-21 16-24 17-18  
18-19 18-28 19-20 19-28 20-21 21-22 22-23 23-24

exact/norm bonds :

1-2 1-6 1-9 2-3 3-4 4-5 4-25 5-6 5-25 6-7 7-8 8-9 12-13 12-34 13-14 13-15  
16-17 16-21 16-24 17-18 18-19 18-28 19-20 19-28 20-21 21-22 22-23 23-24



G1:C,N

G2:O,N

G3:[\*1],[\*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 12:CLASS 13:CLASS  
14:CLASS 15:CLASS 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom  
24:Atom 25:Atom 28:Atom 34:CLASS



chain nodes :

12 13 15

ring nodes :

1 2 3 4 5 6 7 8 9

ring/chain nodes :

14

chain bonds :

8-12 12-13 13-14 13-15

ring bonds :

1-2 1-6 1-9 2-3 3-4 4-5 5-6 6-7 7-8 8-9

exact/norm bonds :

1-2 1-6 1-9 2-3 3-4 4-5 5-6 6-7 7-8 8-9 8-12 12-13 13-14 13-15

G1:C,N

G2:O,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 12:CLASS 13:CLASS  
14:CLASS 15:CLASS

=>


Uploading 10015332.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,N

G2 O,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 18:59:33 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 73 TO ITERATE

100.0% PROCESSED 73 ITERATIONS

32 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 948 TO 1972

PROJECTED ANSWERS: 301 TO 979

L2 32 SEA SSS SAM L1

=>


Uploading 10015332.str

L3 STRUCTURE UPLOADED

=> d l3

L3 HAS NO ANSWERS

L3 STR



G1 C,N

G2 O,N

Structure attributes must be viewed using STN Express query preparation.

=> s 13 sss sam

SAMPLE SEARCH INITIATED 19:01:27 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 73 TO ITERATE

100.0% PROCESSED 73 ITERATIONS

11 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 948 TO 1972

PROJECTED ANSWERS: 22 TO 418

L4 11 SEA SSS SAM L3

=> s 13 sss ful

FULL SEARCH INITIATED 19:01:58 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1622 TO ITERATE

100.0% PROCESSED 1622 ITERATIONS

125 ANSWERS

SEARCH TIME: 00.00.01

L5 125 SEA SSS FUL L3


=> s 15

L6 1 L5

=> d 16 bib,ab,hitstr


L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS  
 AN 2002:594826 CAPLUS  
 DN 137:140526  
 TI Preparation of benzimidazoles as gyrase inhibitors  
 IN Grillot, Anne-Laure; Charifson, Paul; Stamos, Dean; Liao, Yusheng; Badia, Michael; Trudeau, Martin  
 PA Vertex Pharmaceuticals Incorporated, USA  
 SO PCT Int. Appl., 113 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002060879	A2	20020808	WO 2001-US48855	20011212
	WO 2002060879	A3	20030327		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 2000-256094P	P	20001215		
	US 2001-275292P	P	20010313		
OS	MARPAT 137:140526				
AB	The title compds. [I; Z = O, NR4; W = N, CRa; Ra = H, halo, CF3, etc.; R1 = (un)substituted (hetero)aryl; R2, R3 = halo, CN, SR6, OR6, etc.; R4 = R6, CONR6, COR6, etc.; R5 = R7, Ar, COAr, etc.; Ar = (un)substituted 5-membered heteroaryl, heterocyclyl, carbocyclyl; R6 = aryl, aralkyl, heteroaryl, etc.; R7 = H, alkyl], useful as inhibitors of bacterial gyrase activity for treating bacterial infections in mammals, were prepd. Thus, treating biphenyl-3,4-diamine with cyanogen bromide in THF/MeOH/H2O followed by reacting the resulting 5-phenyl-1H-benzimidazol-2-ylamine with Et isocyanate in THF afforded I [Z = NH; W = CH; R1, R3 = H; R2 = Ph; R5 = CONHET] which showed > 75% the gyrase ATPase inhibition at 10 .mu.M. The present invention also relates to methods for decreasing bacterial quantity in a biol. sample.				
IT	<b>445012-26-0P 445012-27-1P</b> RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (prepn. of benzimidazoles as gyrase inhibitors)				
RN	445012-26-0 CAPLUS				
CN	1H-Imidazole-4-carboxylic acid, 1-[2-[[[(ethylamino)carbonyl]amino]-1H-benzimidazol-5-yl]-, methyl ester (9CI) (CA INDEX NAME)				





RN 445012-27-1 CAPLUS  
CN 1H-Imidazole-4-carboxylic acid, 1-[2-[[ (ethylamino) carbonyl] amino]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)



IT	445010-93-5P	445010-98-0P	445011-01-8P
	445011-02-9P	445011-08-5P	445011-11-0P
	445011-13-2P	445011-15-4P	445011-16-5P
	445011-17-6P	445011-18-7P	445011-20-1P
	445011-21-2P	445011-22-3P	445011-23-4P
	445011-24-5P	445011-25-6P	445011-26-7P
	445011-27-8P	445011-28-9P	445011-29-0P
	445011-30-3P	445011-31-4P	445011-32-5P
	445011-33-6P	445011-34-7P	445011-35-8P
	445011-36-9P	445011-37-0P	445011-38-1P
	445011-39-2P	445011-42-7P	445011-43-8P
	445011-44-9P	445011-55-2P	445011-56-3P
	445011-61-0P	445011-63-2P	445011-69-8P
	445011-70-1P	445011-71-2P	445011-73-4P
	445011-74-5P	445011-75-6P	445011-76-7P
	445011-77-8P	445011-78-9P	445011-79-0P
	445011-80-3P	445011-81-4P	445011-82-5P
	445011-85-8P	445011-86-9P	445011-87-0P
	445011-88-1P	445011-89-2P	445011-90-5P
	445011-92-7P	445011-93-8P	445011-94-9P
	445011-95-0P	445011-96-1P	445011-97-2P
	445011-98-3P	445011-99-4P	445012-00-0P
	445012-01-1P	445012-02-2P	445012-03-3P
	445012-04-4P	445012-05-5P	445012-06-6P
	445012-07-7P	445012-08-8P	445012-09-9P
	445012-10-2P	445012-11-3P	445012-12-4P
	445012-13-5P	445012-14-6P	445012-16-8P
	445012-17-9P	445012-18-0P	445012-19-1P
	445012-20-4P	445012-21-5P	445012-22-6P
	445012-23-7P	445012-24-8P	445012-25-9P
	445012-28-2P	445012-29-3P	445012-30-6P
	445012-31-7P	445012-32-8P	445012-33-9P
	445012-34-0P	445012-35-1P	445012-36-2P
	445012-37-3P	445012-38-4P	445012-39-5P
	445012-40-8P	445012-41-9P	445012-42-0P
	445012-43-1P	445012-44-2P	445012-45-3P
	445012-47-5P	445012-48-6P	445012-49-7P
	445012-50-0P	445012-51-1P	445012-52-2P
	445012-53-3P	445012-54-4P	445012-55-5P
	445012-56-6P	445012-57-7P	445012-58-8P
	445012-59-9P	445012-60-2P	445012-61-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

```




```

RN 445010-93-5 CAPLUS

CN 1-Piperidinecarboxamide, N-(4-bromo-6-phenyl-1H-benzimidazol-2-yl)- (9CI)  
(CA INDEX NAME)


RN 445010-98-0 CAPLUS

CN Urea, N-ethyl-N'-[6,7,8,9-tetrahydro-7-methyl-5-(3-pyridinyl)-1H-imidazo[4,5-f]isoquinolin-2-yl]- (9CI) (CA INDEX NAME)




RN 445011-01-8 CAPLUS

CN Urea, N-ethyl-N'-[5-(8-quinolinyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445011-02-9 CAPLUS

CN Urea, N-ethyl-N'-[5-(1H-indol-6-yl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445011-08-5 CAPLUS

CN Glycine, N-[5-[2-[[ (ethylamino) carbonyl] amino]-1H-benzimidazol-5-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 445011-11-0 CAPLUS


CN Urea, N-cyclopropyl-N'-[5-(3-pyridinyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 445011-13-2 CAPLUS


CN L-Serine, O-(1,1-dimethylethyl)-N-[5-[2-[(ethylamino)carbonylamino]-1H-benzimidazol-5-yl]-2-pyrimidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 445011-15-4 CAPLUS

CN Urea, N-ethyl-N'-[5-methoxy-6-(3-pyridinyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445011-16-5 CAPLUS

CN Urea, N-ethyl-N'-(4-methyl-6-phenyl-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 445011-17-6 CAPLUS


CN Urea, N-[5-[2-(cyclopropylamino)-5-pyrimidinyl]-1H-benzimidazol-2-yl]-N'-ethyl- (9CI) (CA INDEX NAME)



RN 445011-18-7 CAPLUS


CN L-Serine, N-[5-[2-[(ethylamino)carbonyl]amino]-1H-benzimidazol-5-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 445011-20-1 CAPLUS

CN Urea, N-ethyl-N'-[5-[2-[(tetrahydro-2-furanyl)methyl]amino]-5-pyrimidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445011-21-2 CAPLUS

CN Urea, N-ethyl-N'-[5-[2-[(2-pyridinylmethyl)amino]-5-pyrimidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445011-22-3 CAPLUS

CN Urea, N-ethyl-N'-[5-[2-[(4-methoxyphenyl)methyl]amino]-5-pyrimidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445011-23-4 CAPLUS

CN Urea, N-ethyl-N'-(4-methoxy-6-phenyl-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 445011-24-5 CAPLUS

CN Urea, N-ethyl-N'-(4-fluoro-6-phenyl-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 445011-25-6 CAPLUS

CN Urea, N-[5-(2,4-dimethoxy-5-pyrimidinyl)-1H-benzimidazol-2-yl]-N'-ethyl- (9CI) (CA INDEX NAME)




RN 445011-26-7 CAPLUS

CN Urea, N-ethyl-N'-[5-[2-(4-morpholinyl)-5-pyrimidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445011-27-8 CAPLUS

CN Urea, N-[5-(2-amino-5-pyrimidinyl)-1H-benzimidazol-2-yl]-N'-ethyl- (9CI) (CA INDEX NAME)




RN 445011-28-9 CAPLUS

CN Urea, N-ethyl-N'-[5-[2-[[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445011-29-0 CAPLUS

CN Urea, N-ethyl-N'-[5-[2-[[[3-fluorophenyl)methyl]amino]-5-pyrimidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445011-30-3 CAPLUS

CN Urea, N-ethyl-N'-[5-[2-(1-pyrrolidinylamino)-5-pyrimidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445011-31-4 CAPLUS

CN Urea, N-ethyl-N'-[4-methyl-6-(3-pyridinyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445011-32-5 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[2-[[ (ethylamino) carbonyl] amino]-1H-benzimidazol-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 445011-33-6 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[2-[[ (ethylamino) carbonyl] amino]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 445011-34-7 CAPLUS

CN Urea, N-[5-[2-[(3-chloro-4-fluorophenyl)methyl]amino]-5-pyrimidinyl]-1H-benzimidazol-2-yl]-N'-ethyl- (9CI) (CA INDEX NAME)




RN 445011-35-8 CAPLUS

CN Urea, N-ethyl-N'-[5-fluoro-6-(3-pyridinyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 445011-36-9 CAPLUS


CN Urea, N-ethyl-N'-[5-[2-[[2-(2-pyridinyl)ethyl]amino]-5-pyrimidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 445011-37-0 CAPLUS


CN Urea, N-ethyl-N'-[5-[2-(4-methyl-1-piperazinyl)-5-pyrimidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)






RN 445011-38-1 CAPLUS

CN Urea, N-ethyl-N'-[5-[2-(1-pyrrolidiny)-5-pyrimidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445011-39-2 CAPLUS

CN Urea, N-ethyl-N'-[5-[2-(ethylamino)-5-pyrimidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445011-42-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-[2-[[ (ethylamino)carbonyl]amino]-1H-benzimidazol-5-yl]-2-pyrimidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 445011-43-8 CAPLUS

CN Urea, N-ethyl-N'-[5-[2-(1-piperazinyl)-5-pyrimidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445011-44-9 CAPLUS

CN Urea, N-[5-(1,6-dihydro-6-oxo-3-pyridinyl)-1H-benzimidazol-2-yl]-N'-ethyl- (9CI) (CA INDEX NAME)




RN 445011-55-2 CAPLUS

CN 1H-Pyrazole-4-carboxamide, N-acetyl-1-[2-[(ethylamino)carbonyl]amino]-1H-imidazo[4,5-b]pyridin-5-yl]- (9CI) (CA INDEX NAME)




RN 445011-56-3 CAPLUS

CN Urea, N-ethyl-N'-(5-phenyl-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 445011-61-0 CAPLUS

CN Urea, N-(4-bromo-6-phenyl-1H-benzimidazol-2-yl)-N'-ethyl- (9CI) (CA INDEX NAME)




RN 445011-63-2 CAPLUS

CN Urea, N-ethyl-N'-[5-[2-(methylthio)-5-pyrimidinyl]-1H-benzimidazol-2-yl]-  
(9CI) (CA INDEX NAME)




RN 445011-69-8 CAPLUS

CN Urea, N-ethyl-N'-[5-[2-[(3-pyridinylmethyl)amino]-5-pyrimidinyl]-1H-  
benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445011-70-1 CAPLUS

CN 1H-Imidazole-4-carboxamide, N-acetyl-1-[2-[[ (ethylamino) carbonyl] amino]-1H-  
imidazo[4,5-b]pyridin-5-yl]- (9CI) (CA INDEX NAME)




RN 445011-71-2 CAPLUS

CN Urea, N-ethyl-N'-[5-[2-[(2-methoxy-1-methylethyl)amino]-5-pyrimidinyl]-1H-  
benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445011-73-4 CAPLUS

CN Urea, N-ethyl-N'-[5-[2-[(3-methoxypropyl)amino]-5-pyrimidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445011-74-5 CAPLUS

CN Urea, N-ethyl-N'-[4-fluoro-6-(3-pyridinyl)-1H-benzimidazol-2-yl]- (9CI)  
(CA INDEX NAME)




RN 445011-75-6 CAPLUS

CN Urea, N-[4-cyano-6-(3-pyridinyl)-1H-benzimidazol-2-yl]-N'-ethyl- (9CI)  
(CA INDEX NAME)




RN 445011-76-7 CAPLUS

CN 1H-Benzimidazole-4-carboxylic acid, 2-[[ (ethylamino) carbonyl] amino]-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 445011-77-8 CAPLUS

CN Urea, N-ethyl-N'-[5-[2-[(2-(1-methyl-2-pyrrolidinyl)ethyl)amino]-5-pyrimidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445011-78-9 CAPLUS

CN Urea, N-[4-amino-6-(3-pyridinyl)-1H-benzimidazol-2-yl]-N'-ethyl- (9CI) (CA INDEX NAME)



RN 445011-79-0 CAPLUS


CN Urea, N-ethyl-N'-[4-methoxy-6-(3-pyridinyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 445011-80-3 CAPLUS


CN Urea, N-[5-[2-(3,5-dimethyl-1-piperidinyl)-5-pyrimidinyl]-1H-benzimidazol-

2-yl]-N'-ethyl- (9CI) (CA INDEX NAME)




RN 445011-81-4 CAPLUS

CN Urea, N-ethyl-N'-[5-methoxy-6-(2-methoxy-5-pyrimidinyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445011-82-5 CAPLUS

CN Piperazine, 1-acetyl-4-[5-[2-[(ethylamino) carbonyl] amino]-1H-benzimidazol-5-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 445011-85-8 CAPLUS

CN Urea, N-(1-methylethyl)-N'-[5-[2-(methylthio)-5-pyrimidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445011-86-9 CAPLUS

CN Urea, N-cyclopentyl-N'-[5-[2-(methylthio)-5-pyrimidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445011-87-0 CAPLUS

CN Urea, N-ethyl-N'-[5-(3-pyridinyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445011-88-1 CAPLUS

CN Urea, N-propyl-N'-[5-(3-pyridinyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445011-89-2 CAPLUS

CN Urea, N-(1-methylethyl)-N'-[5-(3-pyridinyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445011-90-5 CAPLUS


CN Urea, N-cyclopentyl-N'-[5-(3-pyridinyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445011-92-7 CAPLUS  
 CN Benzoic acid, 3-[2-[[ (ethylamino) carbonyl] amino]-1H-benzimidazol-5-yl]-  
 (9CI) (CA INDEX NAME)




RN 445011-93-8 CAPLUS  
 CN Piperazine, 1-[5-[2-[[ (ethylamino) carbonyl] amino]-1H-benzimidazol-5-yl]-2-pyrimidinyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 445011-94-9 CAPLUS  
 CN Urea, N-ethyl-N'-[5-[2-(4-hydroxy-1-piperidinyl)-5-pyrimidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445011-95-0 CAPLUS  
 CN Urea, N-[5-(2-amino-5-pyrimidinyl)-6-methoxy-1H-benzimidazol-2-yl]-N'-ethyl- (9CI) (CA INDEX NAME)




RN 445011-96-1 CAPLUS  
 CN Urea, N-[5-[2-[(cyclopropylmethyl)propylamino]-5-pyrimidinyl]-1H-benzimidazol-2-yl]-N'-ethyl- (9CI) (CA INDEX NAME)






RN 445011-97-2 CAPLUS

CN Urea, N-[5-[2-[(1,3-benzodioxol-5-ylmethyl)amino]-5-pyrimidinyl]-1H-benzimidazol-2-yl]-N'-ethyl- (9CI) (CA INDEX NAME)




RN 445011-98-3 CAPLUS

CN Urea, N-ethyl-N'-[5-[2-(3-hydroxy-1-pyrrolidinyl)-5-pyrimidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445011-99-4 CAPLUS

CN Urea, N-ethyl-N'-[5-[2-[2-(methoxymethyl)-1-pyrrolidinyl]-5-pyrimidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445012-00-0 CAPLUS

CN Urea, N-[5-(2-amino-5-pyrimidinyl)-6-fluoro-1H-benzimidazol-2-yl]-N'-ethyl- (9CI) (CA INDEX NAME)




RN 445012-01-1 CAPLUS

CN Urea, N-ethyl-N'-[5-(6-methoxy-3-pyridinyl)-1H-benzimidazol-2-yl]- (9CI)  
(CA INDEX NAME)




RN 445012-02-2 CAPLUS

CN Urea, N-ethyl-N'-[5-methyl-6-(3-pyridinyl)-1H-benzimidazol-2-yl]- (9CI)  
(CA INDEX NAME)




RN 445012-03-3 CAPLUS

CN Urea, N-[4-chloro-6-(3-pyridinyl)-1H-benzimidazol-2-yl]-N'-ethyl- (9CI)  
(CA INDEX NAME)




RN 445012-04-4 CAPLUS

CN Carbamic acid, [[4-[7-chloro-2-[(ethylamino)carbonylamino]-1H-benzimidazol-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 445012-05-5 CAPLUS

CN Urea, N-ethyl-N'-[5-(6-fluoro-3-pyridinyl)-1H-benzimidazol-2-yl]- (9CI)  
(CA INDEX NAME)




RN 445012-06-6 CAPLUS

CN Urea, N-[5-[4-(aminomethyl)phenyl]-1H-benzimidazol-2-yl]-N'-ethyl- (9CI)  
(CA INDEX NAME)




RN 445012-07-7 CAPLUS

CN Methanesulfonamide, N-[[4-[2-[[ (ethylamino) carbonyl] amino]-1H-benzimidazol-5-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 445012-08-8 CAPLUS

CN Acetamide, N-[[4-[2-[[ (ethylamino) carbonyl] amino]-1H-benzimidazol-5-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 445012-09-9 CAPLUS

CN Urea, N-ethyl-N'-[5-methoxy-6-[2-(2-methoxy-1-methylethoxy)-5-pyrimidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445012-10-2 CAPLUS

CN Urea, N-ethyl-N'-[6-[2-(2-methoxy-1-methylethoxy)-5-pyrimidinyl]-4-methyl-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 445012-11-3 CAPLUS


CN Urea, N-[4,5-dimethyl-6-(3-pyridinyl)-1H-benzimidazol-2-yl]-N'-ethyl- (9CI) (CA INDEX NAME)




RN 445012-12-4 CAPLUS

CN Imidodicarbonic acid, [[5-[2-[[[(ethylamino)carbonyl]amino]-1H-benzimidazol-5-yl]-2-pyridinyl]methyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX

NAME)




RN 445012-13-5 CAPLUS

CN Urea, N-[5-[6-(aminomethyl)-3-pyridinyl]-1H-benzimidazol-2-yl]-N'-ethyl-  
(9CI) (CA INDEX NAME)


RN 445012-14-6 CAPLUS

CN Acetamide, N-[[5-[2-[[[(ethylamino)carbonyl]amino]-1H-benzimidazol-5-yl]-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 445012-16-8 CAPLUS


CN Urea, N-ethyl-N'-[5-methoxy-6-[2-[(2-methoxy-1-methylethyl)amino]-5-pyrimidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 445012-17-9 CAPLUS


CN Urea, N-ethyl-N'-[5-methoxy-4-methyl-6-(3-pyridinyl)-1H-benzimidazol-2-yl]-

(9CI) (CA INDEX NAME)




RN 445012-18-0 CAPLUS

CN Carbamic acid, [[5-[2-[(ethylamino)carbonylamino]-1H-benzimidazol-5-yl]-2-pyridinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 445012-19-1 CAPLUS

CN Urea, N-ethyl-N'-[5-(2-methoxyethoxy)-4-methyl-6-(3-pyridinyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445012-20-4 CAPLUS

CN Urea, N-ethyl-N'-[5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445012-21-5 CAPLUS

CN Urea, N-ethyl-N'-[5-(1,3,4-oxadiazol-2-yl)-1H-benzimidazol-2-yl]- (9CI)  
(CA INDEX NAME)




RN 445012-22-6 CAPLUS

CN Urea, N-[5-(2,3-difluorophenyl)-1H-benzimidazol-2-yl]-N'-ethyl- (9CI) (CA INDEX NAME)




RN 445012-23-7 CAPLUS

CN Urea, N-[2,2-difluoro-4-(3-pyridinyl)-6H-1,3-dioxolo[4,5-e]benzimidazol-7-yl]-N'-ethyl- (9CI) (CA INDEX NAME)




RN 445012-24-8 CAPLUS

CN Methanesulfonamide, N-[[5-[2-[[ (ethylamino) carbonyl] amino]-1H-benzimidazol-5-yl]-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)




RN 445012-25-9 CAPLUS

CN Urea, N-ethyl-N'-[5-(3-fluorophenyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445012-28-2 CAPLUS

CN Urea, N-[5-(1,6-dihydro-6-oxo-2-pyridinyl)-1H-benzimidazol-2-yl]-N'-ethyl- (9CI) (CA INDEX NAME)



RN 445012-29-3 CAPLUS


CN Urea, N-[5-(6-fluoro-3-pyridinyl)-1H-benzimidazol-2-yl]-N'-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 445012-30-6 CAPLUS


CN Urea, N-ethyl-N'-[5-[2-methyl-4-oxo-3-(phenylmethoxy)-1(4H)-pyridinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)






RN 445012-31-7 CAPLUS

CN Urea, N-ethyl-N'-[5-(3-hydroxy-2-methyl-4-oxo-1(4H)-pyridinyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445012-32-8 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-[2-[[ (ethylamino)carbonyl]amino]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 445012-33-9 CAPLUS

CN Urea, N-[5-(6-ethoxy-3-pyridinyl)-1H-benzimidazol-2-yl]-N'-ethyl- (9CI) (CA INDEX NAME)




RN 445012-34-0 CAPLUS

CN Urea, N-ethyl-N'-[5-(4-morpholinyl)-6-(3-pyridinyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445012-35-1 CAPLUS

CN Urea, N-ethyl-N'-[5-(2-hydroxyphenyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445012-36-2 CAPLUS

CN Urea, N-ethyl-N'-[5-[6-(4-morpholinyl)-3-pyridinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445012-37-3 CAPLUS

CN Urea, N-ethyl-N'-[6-(3-pyridinyl)-4-(trifluoromethyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445012-38-4 CAPLUS

CN Urea, N-ethyl-N'-[4-(phenylmethoxy)-6-(3-pyridinyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445012-39-5 CAPLUS

CN Urea, N-ethyl-N'-[4-hydroxy-6-(3-pyridinyl)-1H-benzimidazol-2-yl]- (9CI)  
(CA INDEX NAME)




RN 445012-40-8 CAPLUS

CN Morpholine, 4-[[1-[2-[[[(ethylamino)carbonyl]amino]-1H-benzimidazol-5-yl]-1H-pyrazol-4-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 445012-41-9 CAPLUS

CN 1H-Imidazole-4-carboxamide, 1-[2-[[[(ethylamino)carbonyl]amino]-1H-benzimidazol-5-yl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 445012-42-0 CAPLUS

CN Morpholine, 4-[[1-[2-[[ (ethylamino) carbonyl] amino]-1H-benzimidazol-5-yl]-1H-imidazol-4-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 445012-43-1 CAPLUS

CN 1H-Pyrazole-4-carboxamide, 1-[2-[[ (ethylamino) carbonyl] amino]-1H-benzimidazol-5-yl]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 445012-44-2 CAPLUS

CN 1H-Pyrazole-4-carboxamide, 1-[2-[[ (ethylamino) carbonyl] amino]-1H-benzimidazol-5-yl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 445012-45-3 CAPLUS

CN Urea, N-ethyl-N'-[5-[6-(1-piperidinyl)-3-pyridinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 445012-47-5 CAPLUS

CN Urea, N-ethyl-N'-[5-[6-(1-pyrrolidinyl)-3-pyridinyl]-1H-benzimidazol-2-yl]-(9CI) (CA INDEX NAME)




RN 445012-48-6 CAPLUS

CN Urea, N-ethyl-N'-[5-(1-piperidinyl)-6-(3-pyridinyl)-1H-benzimidazol-2-yl]-(9CI) (CA INDEX NAME)





RN 445012-49-7 CAPLUS

CN Urea, N-ethyl-N'-[5-[6-(3-hydroxy-1-pyrrolidinyl)-3-pyridinyl]-1H-benzimidazol-2-yl]-(9CI) (CA INDEX NAME)




RN 445012-50-0 CAPLUS

CN Urea, N-ethyl-N'-[5-(3-pyridinyl)-6-(1-pyrrolidinyl)-1H-benzimidazol-2-yl]-(9CI) (CA INDEX NAME)




RN 445012-51-1 CAPLUS

CN Urea, N-ethyl-N'-[5-(3-hydroxy-4-oxo-4H-pyran-2-yl)-1H-benzimidazol-2-yl]-  
(9CI) (CA INDEX NAME)




RN 445012-52-2 CAPLUS

CN Urea, N-ethyl-N'-[5-[6-(4-pentenyl-2-yl)-3-pyridinyl]-1H-benzimidazol-2-yl]-  
(9CI) (CA INDEX NAME)




RN 445012-53-3 CAPLUS

CN Urea, N-ethyl-N'-[4-fluoro-5-methoxy-6-(3-pyridinyl)-1H-benzimidazol-2-yl]-  
(9CI) (CA INDEX NAME)




RN 445012-54-4 CAPLUS


CN 1H-Imidazole-4-carboxylic acid, 1-[2-[(ethylamino)carbonyl]amino]-1H-




CN 1H-Imidazole-4-carboxylic acid, 1-[2-[[ (ethylamino) carbonyl] amino]-1H-imidazo[4,5-b]pyridin-5-yl]- (9CI) (CA INDEX NAME)




1H-Imidazole-4-carboxamide, N-butyl-1-[2-[[ (ethylamino) carbonyl] amino]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)



CN 1H-Imidazole-4-carboxamide, N-cyclopropyl-1-[2-  
[[ (ethylamino) carbonyl] amino]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX  
NAME)




CN 1H-Imidazole-4-carboxamide, 1-[2-[(ethylamino)carbonyl]amino]-1H-benzimidazol-5-yl]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 445012-59-9 CAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-3-carboxylic acid, 1-[2-  
[[ (ethylamino) carbonyl] amino]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX  
NAME)




RN 445012-60-2 CAPLUS

CN Urea, N-[5-[6-(2-ethoxyethoxy)-3-pyridinyl]-1H-benzimidazol-2-yl]-N'-ethyl-  
(9CI) (CA INDEX NAME)



RN 445012-61-3 CAPLUS

CN Urea, N-[5-[6-(3-amino-1-pyrrolidinyl)-3-pyridinyl]-1H-benzimidazol-2-yl]-  
N'-ethyl- (9CI) (CA INDEX NAME)





=&gt; d his

(FILE 'HOME' ENTERED AT 18:59:06 ON 01 MAY 2003)

FILE 'REGISTRY' ENTERED AT 18:59:10 ON 01 MAY 2003

L1               STRUCTURE UPLOADED  
 L2               32 S L1 SSS SAM  
 L3               STRUCTURE UPLOADED  
 L4               11 S L3 SSS SAM  
 L5               125 S L3 SSS FUL

FILE 'CAPLUS' ENTERED AT 19:02:08 ON 01 MAY 2003

L6               1 S L5

FILE 'CAOLD' ENTERED AT 19:02:37 ON 01 MAY 2003

=&gt; s l5

L7               0 L5

=&gt;

Uploading 10015332 (sub).str

L8               STRUCTURE UPLOADED

=&gt; s l8 sub=l5 sss sam

SAMPLE SUBSET SEARCH INITIATED 19:03:58 FILE 'REGISTRY'

SAMPLE SUBSET SCREEN SEARCH COMPLETED -       11 TO ITERATE

100.0% PROCESSED       11 ITERATIONS

11 ANSWERS

SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):

ONLINE   \*\*COMPLETE\*\*

PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):

22 TO       418

PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):

22 TO       418

L9               11 SEA SUB=L5 SSS SAM L8

=&gt; s l8 sss sam

SAMPLE SEARCH INITIATED 19:04:08 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED -       73 TO ITERATE

100.0% PROCESSED       73 ITERATIONS

32 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:   ONLINE   \*\*COMPLETE\*\*

BATCH   \*\*COMPLETE\*\*

PROJECTED ITERATIONS:       948 TO       1972

PROJECTED ANSWERS:       301 TO       979

L10              32 SEA SSS SAM L8

=&gt; s l8 sss ful

FULL SEARCH INITIATED 19:04:17 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED -   1622 TO ITERATE

100.0% PROCESSED       1622 ITERATIONS

660 ANSWERS

SEARCH TIME: 00.00.01

L11 660 SEA SSS FUL L8

=> s l11 not l5

L12 535 L11 NOT L5

=> s l12

L13 136 L12

=>


Uploading 10015332 (sub2).str

L14 STRUCTURE UPLOADED

=> d l14

L14 HAS NO ANSWERS

L14 STR



G1 C,N

G2 O,N

Structure attributes must be viewed using STN Express query preparation.

=> s l14 sub=l11 sss sam

SAMPLE SUBSET SEARCH INITIATED 19:07:03 FILE 'REGISTRY'

SAMPLE SUBSET SCREEN SEARCH COMPLETED - 32 TO ITERATE

100.0% PROCESSED 32 ITERATIONS

11 ANSWERS

SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):

ONLINE \*\*COMPLETE\*\*

PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):

301 TO 979

PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):

22 TO 418

L15 11 SEA SUB=L11 SSS SAM L14

=> s l14 sub=l11 sss ful

FULL SUBSET SEARCH INITIATED 19:08:18 FILE 'REGISTRY'

FULL SUBSET SCREEN SEARCH COMPLETED - 660 TO ITERATE

100.0% PROCESSED 660 ITERATIONS

126 ANSWERS

SEARCH TIME: 00.00.01

L16 126 SEA SUB=L11 SSS FUL L14

=> s l16 not l5

L17 1 L16 NOT L5

=>

Uploading 10015332 (sub3).str

L19        STRUCTURE UPLOADED

=> d 119

L19 HAS NO ANSWERS

L19                STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -    AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s 119 sub=l11 sss sam

SAMPLE SUBSET SEARCH INITIATED 19:14:11 FILE 'REGISTRY'

SAMPLE SUBSET SCREEN SEARCH COMPLETED -        32 TO ITERATE

100.0% PROCESSED        32 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):

ONLINE

\*\*COMPLETE\*\*

PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):

301 TO

979

PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):

0 TO

0

L20                0 SEA SUB=L11 SSS SAM L19

=> s 119 sub=l11 sss ful

FULL SUBSET SEARCH INITIATED 19:14:25 FILE 'REGISTRY'

FULL SUBSET SCREEN SEARCH COMPLETED -        660 TO ITERATE

100.0% PROCESSED        660 ITERATIONS

15 ANSWERS

SEARCH TIME: 00.00.01

L21                15 SEA SUB=L11 SSS FUL L19

=> s 121

L22                5 L21

=> d 122 1-5 bib,ab,hitstr

L22 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS

AN 2002:594826 CAPLUS

DN 137:140526

TI Preparation of benzimidazoles as gyrase inhibitors

IN Grillot, Anne-Laure; Charifson, Paul; Stamos, Dean; Liao, Yusheng; Badia, Michael; Trudeau, Martin

PA Vertex Pharmaceuticals Incorporated, USA

SO PCT Int. Appl., 113 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002060879	A2	20020808	WO 2001-US48855	20011212
	WO 2002060879	A3	20030327		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI US 2000-256094P P 20001215

US 2001-275292P P 20010313

OS MARPAT 137:140526

AB The title compds. [I; Z = O, NR4; W = N, CRa; Ra = H, halo, CF3, etc.; R1 = (un)substituted (hetero)aryl; R2, R3 = halo, CN, SR6, OR6, etc.; R4 = R6, CONR6, COR6, etc.; R5 = R7, Ar, COAr, etc.; Ar = (un)substituted 5-membered heteroaryl, heterocyclyl, carbocyclyl; R6 = aryl, aralkyl, heteroaryl, etc.; R7 = H, alkyl], useful as inhibitors of bacterial gyrase activity for treating bacterial infections in mammals, were prepd. Thus, treating biphenyl-3,4-diamine with cyanogen bromide in THF/MeOH/H2O followed by reacting the resulting 5-phenyl-1H-benzimidazol-2-ylamine with Et isocyanate in THF afforded I [Z = NH; W = CH; R1, R3 = H; R2 = Ph; R5 = CONHET] which showed > 75% the gyrase ATPase inhibition at 10 .mu.M. The present invention also relates to methods for decreasing bacterial quantity in a biol. sample.


IT 445010-98-0P 445012-23-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of benzimidazoles as gyrase inhibitors)


RN 445010-98-0 CAPLUS

CN Urea, N-ethyl-N'-[6,7,8,9-tetrahydro-7-methyl-5-(3-pyridinyl)-1H-imidazo[4,5-f]isoquinolin-2-yl]- (9CI) (CA INDEX NAME)



RN 445012-23-7 CAPLUS

CN Urea, N-[2,2-difluoro-4-(3-pyridinyl)-6H-1,3-dioxolo[4,5-e]benzimidazol-7-yl]-N'-ethyl- (9CI) (CA INDEX NAME)



L22 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS

AN 1999:566045 CAPLUS

DN 131:199702

TI Preparation of imidazoquinazoline derivatives or analogs thereof for treatment of erectile dysfunction

IN Onoda, Yasuo; Takami, Hitoshi; Seishi, Takashi; Machii, Daisuke; Nomoto, Yuji; Takai, Haruki; Okumura, Hiroshi; Ohno, Tetsuji; Yamada, Koji; Ichimura, Michio

PA Kyowa Hakko Kogyo Co., Ltd., Japan

SO PCT Int. Appl., 100 pp.


CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9943674	A1	19990902	WO 1999-JP920	19990226
	W: AU, BG, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RO, SG, SI, SK, UA, US, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9926411	A1	19990915	AU 1999-26411	19990226
PRAI	JP 1998-48329		19980227		
	WO 1999-JP920		19990226		
OS	MARPAT 131:199702				
AB	The title compds. I [R1, R2 = H, (un)substituted alkyl, etc.; R3 = H, (un)substituted alkyl, etc.; Y represents N or CH; X1X2X3 represents N:NNR7, NHC(:NCN)NR7, etc.; R7 = H, (un)substituted alkyl, etc.] are prepd. Formulations contg. a compd. of this invention are given. I have a potent and selective cGMP-specific phosphodiesterase (PDE) inhibitory effect and are useful in treating or relieving sexual impotence, etc. The title compd. I.2HCl [X1X2X3 = NHC(:S)N(Et); Y = N; R1 = 4-dimethylaminobenzyl; R2 = H; R3 = methyl] in vitro at 1 nM gave 86% inhibition of PDE V.				
IT	<b>241815-57-6P 241815-58-7P</b>				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(prepn. of imidazoquinazoline derivs. or analogs thereof for treatment of erectile dysfunction)				
RN	241815-57-6 CAPLUS				
CN	Urea, [3-ethyl-8-[(2-pyridinylmethyl)amino]-3H-imidazo[4,5-g]quinazolin-2-yl]-, dihydrochloride (9CI) (CA INDEX NAME)				



● 2 HCl

RN 241815-58-7 CAPLUS

CN Urea, [3-ethyl-8-[(2-pyridinylmethyl)amino]-3H-imidazo[4,5-g]quinazolin-2-yl]- (9CI) (CA INDEX NAME)



RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS  
 AN 1979:137814 CAPLUS  
 DN 90:137814  
 TI N-Heterocyclic ureas as immune regulants  
 IN Paget, Charles J.; Sands, John L.  
 PA Lilly, Eli, and Co., USA  
 SO U.S., 13 pp.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4088768	A	19780509	US 1976-651322	19760121
	CA 966124	A1	19750415	CA 1970-73189	19700127
	US 4153709	A	19790508	US 1977-843775	19771020
	US 4171364	A	19791016	US 1978-965358	19781130
	US 4208419	A	19800617	US 1978-965357	19781130
PRAI	US 1969-794756		19690128		
	US 1971-185823		19711001		
	US 1975-574991		19750506		
	US 1973-398607		19730919		
	US 1975-574997		19750506		
	US 1976-651322		19760121		
	US 1977-843775		19771020		


AB The urea I (X = NH, R = H, R1 = Ph, R2 = 6-OMe) was used as immunosuppressant. I (X = NH, NPh, NMe, O, S; R = H, Me; R1 = Ph, substituted Ph, naphthyl; R2 = H, Cl, CO2Et, CF3, 5,6-Me2, NO2, benzo, OMe) (144 compds.) were prepd. Thus, 2-aminobenzimidazole was treated with 1-naphthyl isocyanate to give I (X = NH, R = R2 = H, R1 = 1-naphthyl) which at 3.1 mg/kg i.p. 3 times in mice gave 4-fold decrease in hemagglutination titer.

IT **24370-18-1P 24370-19-2P 24370-44-3P**  
**24370-45-4P 24370-46-5P 24370-47-6P**  
**24370-48-7P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. and immunosuppressant activity of)

RN 24370-18-1 CAPLUS


CN Urea, N-(3-chlorophenyl)-N'-1H-naphth[1,2-d]imidazol-2-yl- (9CI) (CA INDEX NAME)



RN 24370-19-2 CAPLUS


CN Urea, N-(4-fluorophenyl)-N'-1H-naphth[1,2-d]imidazol-2-yl- (9CI) (CA INDEX NAME)






RN 24370-44-3 CAPLUS

CN Urea, N-1H-naphth[2,3-d]imidazol-2-yl-N'-phenyl- (9CI) (CA INDEX NAME)




RN 24370-45-4 CAPLUS

CN Urea, N-1-naphthalenyl-N'-1H-naphth[2,3-d]imidazol-2-yl- (9CI) (CA INDEX NAME)




RN 24370-46-5 CAPLUS

CN Urea, N-(4-fluorophenyl)-N'-1H-naphth[2,3-d]imidazol-2-yl- (9CI) (CA INDEX NAME)




RN 24370-47-6 CAPLUS

CN Urea, N-1H-naphth[1,2-d]imidazol-2-yl-N'-phenyl- (9CI) (CA INDEX NAME)



RN 24370-48-7 CAPLUS

CN Urea, N-1-naphthalenyl-N'-1H-naphth[1,2-d]imidazol-2-yl- (9CI) (CA INDEX NAME)



L22 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS

AN 1970:487920 CAPLUS

DN 73:87920

TI Antiviral and immunization reaction-suppressing compounds containing an N-heterocyclic urea compound

IN Paget, Charles J., Jr.; Sands, John L.

PA Lilly, Eli, and Co.

SO Ger. Offen., 43 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2003841	A	19700730	DE 1970-2003841	19700128
	DE 2003841	B2	19730906		
	DE 2003841	C3	19740411		
	ZA 7000282	A	19710825	ZA 1970-282	19700116
	BE 744970	A	19700727	BE 1970-744970	19700127
	CA 966124	A1	19750415	CA 1970-73189	19700127
	FR 2034500	A1	19701211	FR 1970-2955	19700128
	FR 2034500	A5	19701211		
	GB 1296561	A	19721115	GB 1970-1296561	19700128
PRAI	US 1969-794749		19690128		
	US 1969-794756		19690128		


AB The title compds. (I) are prepd. by treating II with ClC(:Y)NRR1 and Et3N, or with Y:C:NR. Phys. and pharmacol. data on 216 I were given (Q = unsubstituted, mono- and disubstituted .omicron.-C6H4, 1,2-, 2,3-, and 5,6-naphthylene; Z = NH, NR3, and S; Y = O and S; R2 = H and Me; n = 0 and 1; m = 0 and 1; R = cycloalkyl and aryl; R1 = Ph and H).

IT **24370-18-1P 24370-19-2P 24370-31-8P**  
**24370-32-9P 24370-33-0P 24370-44-3P**  
**24370-45-4P 24370-46-5P 24370-47-6P**  
**24370-48-7P 24486-74-6P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of)


RN 24370-18-1 CAPLUS

CN Urea, N-(3-chlorophenyl)-N'-1H-naphth[1,2-d]imidazol-2-yl- (9CI) (CA  
 INDEX NAME)




RN 24370-19-2 CAPLUS

CN Urea, N-(4-fluorophenyl)-N'-1H-naphth[1,2-d]imidazol-2-yl- (9CI) (CA  
 INDEX NAME)




RN 24370-31-8 CAPLUS

CN Urea, 1-(5H-1,3-dioxolo[4,5-f]benzimidazol-6-yl)-3-phenyl- (8CI) (CA INDEX NAME)




RN 24370-32-9 CAPLUS

CN Urea, 1-(5H-1,3-dioxolo[4,5-f]benzimidazol-6-yl)-3-(1-naphthyl)- (8CI) (CA INDEX NAME)




RN 24370-33-0 CAPLUS

CN Urea, 1-cyclohexyl-3-(5H-1,3-dioxolo[4,5-f]benzimidazol-6-yl)- (8CI) (CA INDEX NAME)




RN 24370-44-3 CAPLUS

CN Urea, N-1H-naphth[2,3-d]imidazol-2-yl-N'-phenyl- (9CI) (CA INDEX NAME)




RN 24370-45-4 CAPLUS

CN Urea, N-1-naphthalenyl-N'-1H-naphth[2,3-d]imidazol-2-yl- (9CI) (CA INDEX NAME)




RN 24370-46-5 CAPLUS

CN Urea, N-(4-fluorophenyl)-N'-1H-naphth[2,3-d]imidazol-2-yl- (9CI) (CA INDEX NAME)




RN 24370-47-6 CAPLUS

CN Urea, N-1H-naphth[1,2-d]imidazol-2-yl-N'-phenyl- (9CI) (CA INDEX NAME)




RN 24370-48-7 CAPLUS

CN Urea, N-1-naphthalenyl-N'-1H-naphth[1,2-d]imidazol-2-yl- (9CI) (CA INDEX NAME)




RN 24486-74-6 CAPLUS


CN Urea, 1-cyclohexyl-3-(1H-naphth[2,3-d]imidazol-2-yl)- (8CI) (CA INDEX NAME)




L22 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS  
 AN 1970:12644 CAPLUS  
 DN 72:12644  
 TI Heterocyclic substituted ureas. I. Immunosuppression and virus inhibition by benzimidazolylureas  
 AU Paget, Charles J.; Kisner, Kiem; Stone, Robert Louis; DeLong, Donald C.  
 CS Lilly Res. Lab., Eli Lilly and Co., Indianapolis, IN, USA  
 SO Journal of Medicinal Chemistry (1969), 12(5), 1010-15  
 CODEN: JMCMAR; ISSN: 0022-2623  
 DT Journal  
 LA English  
 AB In an effort to define the structure-activity relationships (SAR) for immunosuppression and antiviral activity, a series of 1-(benzimidazol-2-yl)-3-substituted-ureas and their close analogs have been synthesized. Many of these compds. display potent immunosuppression in the sheep erythrocyte test in mice, the most effective being approx. 2000 times as active as azathioprine. In addn., these compds. have potent in vivo antiviral activity in several viral diseases. We have defined the antiviral SAR using mice infected with coxsackie vi rus A21.  
 IT 24370-18-1P 24370-19-2P 24370-31-8P  
 24370-32-9P 24370-33-0P 24370-44-3P  
 24370-45-4P 24370-46-5P 24370-47-6P  
 24370-48-7P 24486-74-6P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of)  
 RN 24370-18-1 CAPLUS  
 CN Urea, N-(3-chlorophenyl)-N'-1H-naphth[1,2-d]imidazol-2-yl- (9CI) (CA INDEX NAME)



RN 24370-19-2 CAPLUS  
 CN Urea, N-(4-fluorophenyl)-N'-1H-naphth[1,2-d]imidazol-2-yl- (9CI) (CA INDEX NAME)




RN 24370-31-8 CAPLUS  
 CN Urea, 1-(5H-1,3-dioxolo[4,5-f]benzimidazol-6-yl)-3-phenyl- (8CI) (CA INDEX NAME)




RN 24370-32-9 CAPLUS

CN Urea, 1-(5H-1,3-dioxolo[4,5-f]benzimidazol-6-yl)-3-(1-naphthyl)- (8CI)  
(CA INDEX NAME)




RN 24370-33-0 CAPLUS

CN Urea, 1-cyclohexyl-3-(5H-1,3-dioxolo[4,5-f]benzimidazol-6-yl)- (8CI) (CA INDEX NAME)



RN 24370-44-3 CAPLUS


CN Urea, N-1H-naphth[2,3-d]imidazol-2-yl-N'-phenyl- (9CI) (CA INDEX NAME)



RN 24370-45-4 CAPLUS


CN Urea, N-1-naphthalenyl-N'-1H-naphth[2,3-d]imidazol-2-yl- (9CI) (CA INDEX NAME)






RN 24370-46-5 CAPLUS

CN Urea, N-(4-fluorophenyl)-N'-1H-naphth[2,3-d]imidazol-2-yl- (9CI) (CA INDEX NAME)




RN 24370-47-6 CAPLUS

CN Urea, N-1H-naphth[1,2-d]imidazol-2-yl-N'-phenyl- (9CI) (CA INDEX NAME)




RN 24370-48-7 CAPLUS

CN Urea, N-1-naphthalenyl-N'-1H-naphth[1,2-d]imidazol-2-yl- (9CI) (CA INDEX NAME)



RN 24486-74-6 CAPLUS

CN Urea, 1-cyclohexyl-3-(1H-naphth[2,3-d]imidazol-2-yl)- (8CI) (CA INDEX NAME)



=&gt; d his

(FILE 'HOME' ENTERED AT 18:59:06 ON 01 MAY 2003)

FILE 'REGISTRY' ENTERED AT 18:59:10 ON 01 MAY 2003

L1 STRUCTURE UPLOADED  
 L2 32 S L1 SSS SAM  
 L3 STRUCTURE UPLOADED  
 L4 11 S L3 SSS SAM  
 L5 125 S L3 SSS FUL

FILE 'CAPLUS' ENTERED AT 19:02:08 ON 01 MAY 2003

L6 1 S L5

FILE 'CAOLD' ENTERED AT 19:02:37 ON 01 MAY 2003

L7 0 S L5

FILE 'REGISTRY' ENTERED AT 19:02:54 ON 01 MAY 2003

L8 STRUCTURE UPLOADED  
 L9 11 S L8 SSS SAM SUB=L5  
 L10 32 S L8 SSS SAM  
 L11 660 S L8 SSS FUL  
 L12 535 S L11 NOT L5

FILE 'CAPLUS' ENTERED AT 19:04:32 ON 01 MAY 2003

L13 136 S L12

FILE 'REGISTRY' ENTERED AT 19:05:35 ON 01 MAY 2003

L14 STRUCTURE UPLOADED  
 L15 11 S L14 SSS SAM SUB=L11  
 L16 126 S L14 SSS FUL SUB=L11  
 L17 1 S L16 NOT L5

FILE 'CAPLUS' ENTERED AT 19:08:45 ON 01 MAY 2003

L18 1 S L17

FILE 'REGISTRY' ENTERED AT 19:13:04 ON 01 MAY 2003

L19 STRUCTURE UPLOADED  
 L20 0 S L19 SSS SAM SUB=L11  
 L21 15 S L19 SSS FUL SUB=L11

FILE 'CAPLUS' ENTERED AT 19:14:34 ON 01 MAY 2003

L22 5 S L21

FILE 'CAOLD' ENTERED AT 19:15:31 ON 01 MAY 2003

=&gt; s 121

L23 0 L21

=&gt; log y

COST IN U.S. DOLLARS

SINCE FILE  
ENTRYTOTAL  
SESSION

FULL ESTIMATED COST

0.40

409.46

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE  
ENTRYTOTAL  
SESSION

CA SUBSCRIBER PRICE

0.00

-4.56

10/015,332

STN INTERNATIONAL LOGOFF AT 19:15:43 ON 01 MAY 2003

L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS  
 AN 2002:594826 CAPLUS  
 DN 137:140526  
 TI Preparation of benzimidazoles as gyrase inhibitors  
 IN Grillot, Anne-Laure; Charifson, Paul; Stamos, Dean; Liao, Yusheng; Badia, Michael; Trudeau, Martin  
 PA Vertex Pharmaceuticals Incorporated, USA  
 SO PCT Int. Appl., 113 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002060879	A2	20020808	WO 2001-US48855	20011212
	WO 2002060879	A3	20030327		
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		

PRAI US 2000-256094P P 20001215  
 US 2001-275292P P 20010313

OS MARPAT 137:140526

AB The title compds. [I; Z = O, NR4; W = N, CRA; Ra = H, halo, CF3, etc.; R1 = (un)substituted (hetero)aryl; R2, R3 = halo, CN, SR6, OR6, etc.; R4 = R6, CONR6, COR6, etc.; R5 = R7, Ar, COAr, etc.; Ar = (un)substituted 5-membered heteroaryl, heterocyclyl, carbocyclyl; R6 = aryl, aralkyl, heteroaryl, etc.; R7 = H, alkyl], useful as inhibitors of bacterial gyrase activity for treating bacterial infections in mammals, were prepd. Thus, treating biphenyl-3,4-diamine with cyanogen bromide in THF/MeOH/H2O followed by reacting the resulting 5-phenyl-1H-benzimidazol-2-ylamine with Et isocyanate in THF afforded I [Z = NH; W = CH; R1, R3 = H; R2 = Ph; R5 = CONHET] which showed > 75% the gyrase ATPase inhibition at 10 .mu.M. The present invention also relates to methods for decreasing bacterial quantity in a biol. sample.

IT 445012-46-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of benzimidazoles as gyrase inhibitors)

RN 445012-46-4 CAPLUS

CN Urea, N-ethyl-N'-[5-(4-morpholinyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)

